Related Experiment Videos
Rationale for development of platinum analogs
Abstract:
There is a great need for clinical trial of new second-generation platinum coordination compounds that might demonstrate greater clinical activity in a broader spectrum of tumors, decreased renal toxicity and emesis, improved solubility, synergism in combination therapy, and lack of cross-resistance to cis-dichlorodiammineplatinum(II) (cis-platinum). Lack of cross-resistance to cis-platinum is shown by certain 1,2-diamino-saturated cyclic platinum derivatives which also have a high degree of activity against transplanted mouse leukemias. cis-Platinum and these cyclic compounds combine synergistically with derivatives of cytosine arabinoside, VP-16-213, and Adriamycin. These 1,2-diamino cyclic compounds appear to have less renal toxicity than cis-platinum. The toxic and therapeutic effects of both cis-platinum and the diamino cyclic compounds can be blocked by massive doses of thiourea. Varying doses and time intervals of thiourea rescue are being studied in the hope of improving the therapeutic index of the platinum derivatives.
Insights
New platinum compounds show promise for cancer treatment, offering improved effectiveness and reduced side effects compared to older drugs. These novel agents demonstrate synergistic effects in combination therapies and potential for overcoming resistance to cis-platinum.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- There is a clinical need for novel platinum-based chemotherapy agents with enhanced efficacy and reduced toxicity.
- Existing platinum drugs like cis-dichlorodiammineplatinum(II) (cis-platinum) face challenges including resistance, renal toxicity, and emesis.
- Second-generation platinum coordination compounds are being investigated to address these limitations.
Purpose of the Study:
- To evaluate new second-generation platinum coordination compounds for improved clinical activity across a wider range of tumors.
- To assess the toxicity profile, solubility, and synergistic potential of these novel platinum derivatives.
- To investigate the lack of cross-resistance to cis-platinum and the potential for thiourea rescue.
Main Methods:
- Preclinical evaluation of 1,2-diamino-saturated cyclic platinum derivatives against transplanted mouse leukemias.
- Assessment of synergistic interactions between cis-platinum, cyclic platinum compounds, and other chemotherapeutic agents (cytosine arabinoside, VP-16-213, Adriamycin).
- Investigation of the protective effects of thiourea against the toxic and therapeutic effects of platinum compounds.
Main Results:
- Certain 1,2-diamino-saturated cyclic platinum derivatives exhibit significant activity against mouse leukemias and lack cross-resistance to cis-platinum.
- Synergistic effects were observed when combining cis-platinum and cyclic platinum compounds with cytosine arabinoside, VP-16-213, and Adriamycin.
- These cyclic platinum compounds demonstrated potentially lower renal toxicity compared to cis-platinum.
- Thiourea effectively blocked the toxic and therapeutic effects of both cis-platinum and the diamino cyclic compounds.
Conclusions:
- Second-generation platinum coordination compounds, particularly 1,2-diamino-saturated cyclic derivatives, represent a promising advancement in cancer chemotherapy.
- These novel agents offer potential for broader clinical activity, reduced toxicity, and overcoming cis-platinum resistance.
- Further research into thiourea rescue strategies may improve the therapeutic index of these platinum derivatives.